Ignite Creation Date:
2025-12-25 @ 3:54 AM
Ignite Modification Date:
2026-01-10 @ 2:13 PM
Study NCT ID:
NCT06599502
Status:
ACTIVE_NOT_RECRUITING
Last Update Posted:
2025-11-06
First Post:
2024-08-19
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
A Phase I/IIa Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Efficacy of AZD0022 as Monotherapy and in Combination With Anti-cancer Agents in Adult Participants With Tumours Harbouring a KRASG12D Mutation
Sponsor:
AstraZeneca
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2024-10-18
Start Date Type:
ACTUAL
Primary Completion Date:
2025-10-20
Primary Completion Date Type:
ACTUAL
Completion Date:
2026-06-30
Completion Date Type:
ESTIMATED
First Submit Date:
2024-08-19
First Submit QC Date:
None
Study First Post Date:
2024-09-19
Study First Post Date Type:
ACTUAL
Results First Submit Date:
None
Results First Submit QC Date:
None
Results First Post Date:
None
Results First Post Date Type:
None
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2025-11-05
Last Update Post Date:
2025-11-06
Last Update Post Date Type:
ESTIMATED